|
Mechanism5-HT1A receptor partial agonists [+2] |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanism5-HT2A receptor modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismSARS-CoV-2 S protein inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Center for Excellence and Innovation in Molecular Cell Science, Chinese Academy of Sciences
0 Patents (Medical) associated with Center for Excellence and Innovation in Molecular Cell Science, Chinese Academy of Sciences
100 Deals associated with Center for Excellence and Innovation in Molecular Cell Science, Chinese Academy of Sciences
100 Translational Medicine associated with Center for Excellence and Innovation in Molecular Cell Science, Chinese Academy of Sciences